Zdrowie i gospodarka · 17/06/2011
FDA Releases Draft Guidance on Clinical Trial Endpoints for Non-Small Cell Lung Cancer Drugs and Biologics
The FDA has made available a draft guidance document that outlines recommended endpoints for clinical trials of non-small cell lung cancer drugs and biologics, aiming to streamline the development process and enhance the quality of submitted protocols.